Get started
Author

Jenny Ukena

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
2020 · Aliya A Khan, Mishaela R Rubin, et al. · Journal of Bone and Mineral Research · 113
PDF
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
2024 · Bart L Clarke, Aliya A Khan, et al. · The Journal of Clinical Endocrinology & Metabolism · 45
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
2024 · Lars Rejnmark, Elvira O. Gosmanova, et al. · Advances in Therapy · 45
Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism
2025 · Timothy Graham, Dolores M. Shoback, et al. · Endocrine Practice · 8
PDF
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial
2026 · Mishaela R Rubin, Bart L Clarke, et al. · Journal of Bone and Mineral Research · 7
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial
2024 · Peter Schwarz, Lars Rejnmark, et al. · Endocrine Abstracts · 2
OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
2023 · Bart Clarke, Aliya Aziz Khan, et al. · Journal of the Endocrine Society · 2
PDF
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial
2026 · Lars Rejnmark, Elvira O Gosmanova, et al. · Journal of Bone and Mineral Research · 1
Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism
2026 · Aliya A Khan, Lars Rejnmark, et al. · Journal of the Endocrine Society · 1
Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial
2025 · Kenji Ashida, Masatoshi Nomura, et al. · Endocrine Journal · 1
PDF
OR10-05 Efficacy and Safety of Palopegteriparatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From The Phase 3 PaTHway Trial
2025 · Aliya Aziz Khan, Bart Lyman Clarke, et al. · Journal of the Endocrine Society · 1
PDF
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 pathway trial
2025 · Neil Gittoes, Peter Schwarz, et al. · Endocrine Abstracts · 1
Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial
2024 · Elena Tsourdi, Aliya A. Khan, et al. · Osteologie/Osteology · 1
The impact of parathyroid hormone replacement with palopegteriparatide on synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism
2026 · Michael A. Levine, Jenny Ukena, et al. · Figshare
The impact of parathyroid hormone replacement with palopegteriparatide on synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism
2026 · Michael A. Levine, Jenny Ukena, et al. · Expert Review of Clinical Pharmacology
PDF
OC10.2 - ECE_1406 - Five-year data report from the phase 2 PaTH forward trial of palopegteriparatide for adults with hypoparathyroidism
2026 · Andrea Palermo, Lars Rejnmark, et al. · European Journal of Endocrinology
PDF
Improved Skeletal Dynamics in Adults Treated with Palopegteriparatide for Chronic Hypoparathyroidism: 214-Week Results from the Phase 2 PaTH Forward Trial
2026 · E Tsourdi, M Rubin, et al. · Osteologie/Osteology
Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial
2026 · Neil Gittoes, Andrea Palermo, et al. · Endocrine Abstracts
Efficacy and Safety of Palopegteriparatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From the Phase 3 PaTHway Trial
2026 · Neil Gittoes, Aliya Khan, et al. · Endocrine Abstracts
Improved Skeletal Dynamics in Adults Treated with Palopegteriparatide for Chronic Hypoparathyroidism: 214-Week Results from the Phase 2 PaTH Forward Trial
2026 · Jeremy Turner, Mishaela Rubin, et al. · Endocrine Abstracts
Efficacy and Safety of Palopegteriparatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From the Phase 3 PaTHway Trial
2025 · ALIYA A. KHAN, BART CLARKE, et al. · Canadian Journal of Diabetes
Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial
2025 · ALIYA KHAN, ANDREA PALERMO, et al. · Canadian Journal of Diabetes
Sustained Improvement in Kidney Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: Three-Year Results from the PaTH Forward and PaTHway Trials
2025 · Elvira O. Gosmanova, Peter Schwarz, et al. · Journal of the American Society of Nephrology
Long-term efficacy and safety of palopegteriparatide treatment in adults with chronic hypoparathyroidism: 4-year results from the phase 2 path forward trial
2025 · Andrea Palermo, Aliya Khan, et al. · Endocrine Abstracts
TransCon PTH Improves Health-Related Quality of Life and Reduces Work Limitations in Adults With Hypoparathyroidism: Patient-Reported Outcomes in the Phase 3 PaTHway Trial
2023 · Andrea Palermo, Aliya Khan, et al. · Endocrine Abstracts
Works count: 26
Citation count: 228
H-index: 5
I10-index: 3
Year
Topic
Type